Sanofi Survey Finds Travel Puts Those with Severe Allergies on High Alert

  Sanofi Survey Finds Travel Puts Those with Severe Allergies on High Alert

- Majority of Survey Respondents Reported They or Their Child Experienced a
Severe Allergic Reaction While Traveling -

PR Newswire

BRIDGEWATER, N.J., Aug. 20, 2013

BRIDGEWATER, N.J., Aug. 20, 2013 /PRNewswire/ --In anew nationwide survey*
commissioned by Sanofi US, the makers of Auvi-Q™ (epinephrine injection, USP),
65% of caregivers of children with a severe allergy to food, insect stings or
other causes reported that their child has had a severe allergic reaction
while on vacation.  The nationwide survey, conducted by Wakefield Research, a
leading market research firm, also showed that 70% of adults at risk for
anaphylaxis have had a severe allergic reaction while taking a trip.

To view the multimedia assets associated with this release, please click:
http://www.multivu.com/mnr/62808-sanofi-survey-finds-travel-puts-those-with-severe-allergies-on-high-alert

(Photo 1: http://photos.prnewswire.com/prnh/20130820/MM62080-a )
(Photo 2: http://photos.prnewswire.com/prnh/20130820/MM62080-b )

With Labor Day around the corner – one of the busiest travel weekends of the
year – it is essential that people with a severe allergy are prepared in case
of an emergency. Yet despite guidelines emphasizing the life-saving role of
epinephrine, 68% of adults at risk for anaphylaxis and nearly half (49%) of
all caregivers of children with a severe allergy surveyed, reported to have
forgotten or left behind their or their child's epinephrine auto-injector
while away.

"As someone severely allergic to shellfish and a frequent traveler, I
understand firsthand the importance of being prepared for an unexpected severe
allergic reaction," said football legend Jerome Bettis, who is a spokesperson
for Auvi-Q. "It's critical that I plan ahead. This includes avoiding my
allergen and letting restaurant staff know about my severe allergy; making
sure I always carry my two Auvi-Q epinephrine auto-injectors; and knowing the
number for emergency medical assistance in the area I'm visiting." Bettis has
been working with Sanofi throughout the year on a number of activities to
raise awareness of severe allergies.

Allergy Hot Spots: Whether traveling halfway across the world or one town
away, severe allergies can make travel stressful. In fact, almost all (99%) of
those surveyed said they are worried about experiencing a severe allergic
reaction at one or more outings.

  oWorry spots for caregivers of food allergic children(n=142) include
    restaurants (65%), someone else's home (63%), and picnics or BBQs (59%).
  oThose caring for children with insect sting allergies (n=117) reported
    beingworried at a picnic or BBQ (67%), on vacation (64%), and at the pool
    or beach (61%).

Road Reaction: The risk that comes with eating outside the home for those with
food allergies is very real. Seventy-six percent of thoseadults with a food
allergy that were surveyed (n=176) have had a severe allergic reaction while
on vacation or taking a trip.  Here's how those adults or caregivers of
children living with a food allergy surveyed (n=260) said they manage on the
road:

  o75%responded that they verify all ingredients and preparation methods
    before eating.
  o57%responded that they make allergy-friendly food at home to bring and
    eat.

Don't Let the Bad Bugs Bite: Avoiding bees, wasps and other insects can be a
challenge in the Summer. Seventy percent of those adults with an insect sting
allergy surveyed (n=172) have experienced a severe allergic reaction while on
vacation or taking a trip. What steps do those adults or caregivers of
children living with an insect sting allergy surveyed (n=224) take when going
outdoors?

  oMore than half responded that they wear shoes when outdoors (63%) as well
    as avoid clothes with bright colors and floral patterns (54%).

"Although it is encouraging that many people take steps to manage their risk
for a severe allergic reaction, the high percentage of people surveyed
experiencing anaphylaxis while away still points to the need for increased
education on allergen avoidance and always carrying an epinephrine
auto-injector in case of an emergency," said Dr. Myron Zitt, Associate
Professor of Clinical Medicine at the State University of New York at Stony
Brook, Director of the Adult Allergy Clinic at Nassau University Medical
Center, and consultant to Sanofi US. "I want my patients to enjoy their
vacations, which is why I emphasize the importance of having an action plan in
place to be prepared for an unexpected allergicreaction."

Auvi-Q(epinephrine injection, USP) is the first-and-only epinephrine
auto-injector with audio and visual cues for the emergency treatment of
life-threatening allergic reactions in people who are at risk for or have a
history of anaphylaxis. The size and shape of a credit card and the thickness
of a smartphone, Auvi-Q is a breakthrough in epinephrine auto-injector design
that talks patients and caregivers step-by-step through the injection process.

Additional traveling tips, including how to talk about your severe allergies
in other languages, can be found on Auvi-Q.com. Also available for download is
The Severe Allergy & Anaphylaxis Playbook – a collection of tips to help
educate people living with severe allergies, and their friends and family,
about avoiding allergens and being prepared in case of an emergency – whether
at home or while traveling. 

For additional information and updates, people are encouraged to visit and
"like" Sanofi US' Severe Allergy Awareness Facebook page at
www.Facebook.com/SevereAllergyAwareness.

*Survey Methodology
The survey was conducted by Wakefield Research among 400 respondents,
including 275 adults with a severe allergy who have been prescribed an
epinephrine auto-injector, and 223 caregivers of children under the age of 18
with a severe allergy who have been prescribed an epinephrine auto-injector.
Some survey respondents qualified as both adult sufferers and caregivers of
children with severe allergies. The survey was fielded between July 10 ^ - 22,
2013, using an email invitation and an online survey. The margin of error for
the study is +/- 4.9%.

Indication
Auvi-Q™ (epinephrine injection, USP) is used to treat life-threatening
allergic reactions (anaphylaxis) in people who are at risk for or have a
history of these reactions.

Important Safety Information
Auvi-Q is for immediate self (or caregiver) administration and does not take
the place of emergency medical care. Seek immediate medical treatment after
use. Each Auvi-Q contains a single dose of epinephrine. Auvi-Q should only be
injected into your outer thigh. DO NOT INJECT INTO BUTTOCK OR INTRAVENOUSLY.
If you accidentally inject Auvi-Q into any other part of your body, seek
immediate medical treatment. Epinephrine should be used with caution if you
have heart disease or are taking certain medicines that can cause
heart-related (cardiac) symptoms.

If you take certain medicines, you may develop serious life-threatening side
effects from epinephrine. Be sure to tell your doctor all the medicines you
take, especially medicines for asthma. Side effects may be increased in
patients with certain medical conditions, or who take certain medicines. These
include asthma, allergies, depression, thyroid disease, Parkinson's disease,
diabetes, high blood pressure, and heart disease.

The most common side effects may include increase in heart rate, stronger or
irregular heartbeat, sweating, nausea and vomiting, difficulty breathing,
paleness, dizziness, weakness or shakiness, headache, apprehension,
nervousness, or anxiety. These side effects go away quickly, especially if you
rest.

Talk to your healthcare professional to see if Auvi-Q (epinephrine injection,
USP) is right for you.

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full prescribing information.

For more information about Auvi-Q, visit www.Auvi-Q.com.

About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs,consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

About Wakefield Research
Wakefield Research (http://www.wakefieldresearch.com) is an independent,
global full-service market research consultancy specializing in consumer
research for corporations and organizations throughout the Americas, Europe,
Africa, the Middle East, and Asia. Wakefield Research is a partner to 40 of
the Fortune 100 companies and thousands of smaller companies and
organizations.

SOURCE Sanofi US

Website: http://www.sanofi.us
Contact: Media Relations, Lori Lukus, +1-908-981-3876, lori.lukus@sanofi.com
 
Press spacebar to pause and continue. Press esc to stop.